---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-041238"
form_type: "8-K/A"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:27:02.521810+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed

## Summary
- Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.
- Total revenue of $9.8M from collaboration with Moderna; no revenue in 2021.
- Cash, equivalents, marketable securities $52.0M at Dec 31, 2022; plus $105.3M net from merger and pre-closing financing.
- Merger with Sesen Bio closed March 7, 2023; combined company renamed Carisma Therapeutics Inc.
- Accumulated deficit $158.2M as of Dec 31, 2022; management expects cash runway through end of 2024.

## SEC filing metadata
- accession: 0001104659-23-041238
- form_type: 8-K/A
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/0001104659-23-041238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/tm239286d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-041238
- JSON: https://secwatch.observer/filing/0001104659-23-041238.json
- Plain text: https://secwatch.observer/filing/0001104659-23-041238.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported the year ended December 31, 2022 results: revenue $ 9,834, net income $ (61,226 ), EPS $ (54.65 ).
  - Period: the year ended December 31, 2022
  - Revenue: $ 9,834
  - Net income: $ (61,226 )
  - EPS: $ (54.65 )
  - Result: reported results
  source text: INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31, 2022 2021 Collaboration revenues $ 9,834 $ — Operating expenses: Research and development 56,618 34,387 General and administrative 9,378 6,407 Total operating expenses 65,996 40,794 Operating loss (56,162 ) (40,794 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/0001104659-23-041238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.